Adaptive Biotechnologies (FRA:1HM) Total Liabilities : €317.9 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Total Liabilities?

Adaptive Biotechnologies's Total Liabilities for the quarter that ended in Mar. 2024 was €317.9 Mil.

Adaptive Biotechnologies's quarterly Total Liabilities declined from Sep. 2023 (€333.61 Mil) to Dec. 2023 (€323.57 Mil) and declined from Dec. 2023 (€323.57 Mil) to Mar. 2024 (€317.91 Mil).

Adaptive Biotechnologies's annual Total Liabilities increased from Dec. 2021 (€282.53 Mil) to Dec. 2022 (€370.54 Mil) but then declined from Dec. 2022 (€370.54 Mil) to Dec. 2023 (€323.57 Mil).

Adaptive Biotechnologies Total Liabilities Historical Data

The historical data trend for Adaptive Biotechnologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Total Liabilities Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

307.14

306.73

282.53

370.54

323.57

Adaptive Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															343.26	340.19	333.61	323.57	317.91

Adaptive Biotechnologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Adaptive Biotechnologies's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	80.71	+	(81.969	+	119.815
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	41.075	+	0)
	=	323.6

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	606.26	-	282.691
	=	323.6

Adaptive Biotechnologies's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	76.316	+	(79.948	+	121.021
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	40.627	+	0)
	=	317.9

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	570.697	-	252.785
	=	317.9

Adaptive Biotechnologies Total Liabilities Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (FRA:1HM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ADPT:USA 1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines